BridgeBio(US:BBIO) ZACKS·2026-02-25 01:31分组1 - BridgeBio Pharma reported a quarterly loss of $1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.75, and compared to a loss of $1.31 per share a year ago, indicating a surprise of -34.05% [1] - The company posted revenues of $154.18 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.77%, and showing a significant increase from year-ago revenues of $5.88 million [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] 分组2 - The stock has underperformed the market, losing about 11.2% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.64 on revenues of $173.51 million, and for the current fiscal year, it is -$1.79 on revenues of $900.31 million [7] - The Zacks Industry Rank for Medical - Generic Drugs is currently in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8]